icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Novel anti-viral activity of SB 9200, a RIGI agonist;
results from Cohort 1 of the ACHIEVE trial

 
 
  Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
 
Poster pdf attached
 
Prof. Stephen Locarnini
 
Download the PDF
 

1108171

1108172

1108173

1108174

1108175